PharmaEssentia Corporation
6446
Rank in Stocks
#1366
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Share Price
$39.75
Last synced: 2026-10-16
Market Cap
$16.44B
Change (1 day)
3.73%
Change (1 year)
161.79%
Country
TW
Trade PharmaEssentia Corporation (6446)
Category
Healthcare
EPS for PharmaEssentia Corporation (6446)
EPS as of June 2026 TTM: $0.63
According to PharmaEssentia Corporation latest financial reports and stock price the company's current EPS (TTM) is $0.63. At the end of 2023 the company had a EPS of $-0.06 a decrease compared to its 2022 EPS that were of $-0.14.
EPS history for PharmaEssentia Corporation from 2010 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.63 | 153.00% |
| 2024 | $0.25 | -534.22% |
| 2023 | $-0.06 | -60.15% |
| 2022 | $-0.14 | -59.50% |
| 2021 | $-0.35 | 37.91% |
| 2020 | $-0.25 | 119.47% |
| 2019 | $-0.12 | -14.95% |
| 2018 | $-0.14 | 15.09% |
| 2017 | $-0.12 | 5.89% |
| 2016 | $-0.11 | -6.67% |
| 2015 | $-0.12 | -4.08% |
| 2014 | $-0.13 | 25.60% |
| 2013 | $-0.10 | 63.82% |
| 2012 | $-0.06 | 25.36% |
| 2011 | $-0.05 | 16.87% |
| 2010 | $-0.04 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | -12.05% |
IN
|
